|
🐜
|
MicroRNA gene expression deregulation in human breast cancer.
20 auth.
M. Iorio,
M. Ferracin,
Chang-gong Liu,
A. Veronese,
R. Spizzo,
S. Sabbioni,
E. Magri,
M. Pedriali,
M. Fabbri,
M. Campiglio,
...
S. Ménard,
J. Palazzo,
A. Rosenberg,
P. Musiani,
S. Volinia,
I. Nenci,
G. Calin,
P. Querzoli,
M. Negrini,
C. Croce
|
12 |
2005 |
12
🐜
|
|
🐜
|
MicroRNA signatures in human ovarian cancer.
13 auth.
M. Iorio,
R. Visone,
Gianpiero di Leva,
V. Donati,
F. Petrocca,
P. Casalini,
C. Taccioli,
S. Volinia,
Chang-gong Liu,
H. Alder,
...
G. Calin,
S. Ménard,
C. Croce
|
10 |
2007 |
10
🐜
|
|
🐜
|
Pilot Study of the Mechanism of Action of Preoperative Trastuzumab in Patients with Primary Operable Breast Tumors Overexpressing HER2
15 auth.
R. Gennari,
S. Ménard,
F. Fagnoni,
L. Ponchio,
M. Scelsi,
E. Tagliabue,
F. Castiglioni,
L. Villani,
C. Magalotti,
N. Gibelli,
...
B. Oliviero,
B. Ballardini,
G. D. Prada,
A. Zambelli,
Alberto Costa
|
8 |
2004 |
8
🐜
|
|
🦁
|
Biologic and therapeutic role of HER2 in cancer
S. Ménard,
S. Pupa,
M. Campiglio,
E. Tagliabue
|
8 |
2003 |
8
🦁
|
|
🐜
|
Potential role of HER2‐overexpressing exosomes in countering trastuzumab‐based therapy
14 auth.
V. Ciravolo,
V. Huber,
G. C. Ghedini,
E. Venturelli,
F. Bianchi,
M. Campiglio,
D. Morelli,
A. Villa,
P. D. Mina,
S. Ménard,
...
P. Filipazzi,
L. Rivoltini,
E. Tagliabue,
S. Pupa
|
8 |
2012 |
8
🐜
|
|
🐜
|
Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome
15 auth.
A. Bergamaschi,
E. Tagliabue,
T. Sørlie,
T. Sørlie,
B. Naume,
T. Triulzi,
R. Orlandi,
H. Russnes,
J. Nesland,
R. Tammi,
...
P. Auvinen,
V. Kosma,
S. Ménard,
A. Børresen-Dale,
A. Børresen-Dale
|
8 |
2008 |
8
🐜
|
|
🐜
|
microRNA-205 regulates HER3 in human breast cancer.
9 auth.
M. Iorio,
P. Casalini,
C. Piovan,
Gianpiero di Leva,
A. Merlo,
T. Triulzi,
...
S. Ménard,
C. Croce,
E. Tagliabue
|
8 |
2009 |
8
🐜
|
|
🐬
|
New insights into the role of extracellular matrix during tumor onset and progression
S. Pupa,
S. Ménard,
S. Forti,
E. Tagliabue
|
8 |
2002 |
8
🐬
|
|
🐜
|
Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis.
14 auth.
F. Pezzella,
U. Pastorino,
E. Tagliabue,
S. Andreola,
G. Sozzi,
G. Gasparini,
S. Ménard,
K. Gatter,
A. Harris,
Steve Fox,
...
M. Buyse,
S. Pilotti,
M. Pierotti,
F. Rilke
|
8 |
1997 |
8
🐜
|
|
🐜
|
Characterization of human ovarian carcinoma‐associated antigens defined by novel monoclonal antibodies with tumor‐restricted specificity
9 auth.
S. Miotti,
S. Canevari,
S. Ménard,
D. Mezzanzanica,
Giuliana Porro,
S. Pupa,
...
M. Regazzoni,
E. Tagliabue,
M. Colnaghi
|
8 |
1987 |
8
🐜
|
|
🐜
|
Immunocytochemical markers in stage I lung cancer: relevance to prognosis.
10 auth.
U. Pastorino,
S. Andreola,
E. Tagliabue,
F. Pezzella,
M. Incarbone,
G. Sozzi,
...
M. Buyse,
S. Ménard,
M. Pierotti,
F. Rilke
|
8 |
1997 |
8
🐜
|
|
🦁
|
Role of HER2 gene overexpression in breast carcinoma
S. Ménard,
E. Tagliabue,
M. Campiglio,
S. Pupa
|
8 |
2000 |
8
🦁
|
|
🐜
|
FOXP3 expression and overall survival in breast cancer.
8 auth.
A. Merlo,
P. Casalini,
M. Carcangiu,
Chiara Malventano,
T. Triulzi,
S. Ménard,
...
E. Tagliabue,
A. Balsari
|
8 |
2009 |
8
🐜
|
